Korea S.E.
23:00:00 27/05/2024 BST
5-day change
1st Jan Change
22,700
KRW
+19.54%
+44.59%
+49.24%
DelSiTech Ltd and C-Tri Co. Ltd Sign Collaboration Agreement to Develop Innovative Drug Delivery Technology Product for Oncology
December 18, 2017 at 08:30 am
DelSiTech Ltd. and C-Tri Co. Ltd. have signed a Partnership and Collaboration Agreement to develop long-acting controlled release formulations with significant commercial potential. The first C-Tri product being developed in this partnership is NHM-CT-007, a peptide drug for oncology. DelSiTech's proprietary Silica Matrix technology allows the administration of parenteral controlled release drugs more precisely, safely and cost-effectively than with other alternative drug delivery technologies.
HLB innoVation Co.,Ltd. announced that it has received KRW 55.99999522 billion in funding from a group of investors
12/03/23
CI
HLB innoVation Co.,Ltd. announced that it expects to receive KRW 55.99999522 billion in funding from a group of investors
31/01/23
CI
HLB Pharmaceutical Co., Ltd announced that it has received KRW 20 billion in funding from JW Holdings Corporation, Prime Life & Health Co., Ltd., DongKoo Bio & Pharma Co., Ltd.
09/08/22
CI
HLB Pharmaceutical Co., Ltd announced that it expects to receive KRW 20 billion in funding from JW Holdings Corporation, Prime Life & Health Co., Ltd., DongKoo Bio & Pharma Co., Ltd.
08/08/22
CI
Verismo Therapeutics, Inc. announced that it expects to receive KRW 12.138369345 billion in funding from HLB Pharmaceutical Co., Ltd
05/04/22
CI
G-treeBNT Co., Ltd. announced that it has received KRW 95.000054256 billion in funding from a group of investors
15/11/21
CI
HLB Pharmaceutical Co., Ltd(KOSDAQ:A047920) added to S&P Global BMI Index
20/09/21
CI
HLB Therapeutics Co.,Ltd. announced that it expects to receive KRW 95.000054256 billion in funding from a group of investors
12/09/21
CI
Verismo Therapeutics, Inc. announced that it has received KRW 16.977 billion in funding from HLB Pharmaceutical Co., Ltd
26/04/21
CI
Verismo Therapeutics, Inc. announced that it expects to receive KRW 16.977 billion in funding from HLB Pharmaceutical Co., Ltd
28/03/21
CI
HLB Pharmaceutical Co., Ltd announced that it has received KRW 13.2 billion in funding
11/03/21
CI
HLB Pharmaceutical Co., Ltd announced that it expects to receive KRW 13.2 billion in funding
09/02/21
CI
Mediforum Pharmaceutical Incorporation announced that it has received KRW 20 billion in funding from EBEST Investment & Securities Co., Ltd.
18/10/20
CI
Mediforum Pharmaceutical Incorporation announced that it has received KRW 20 billion in funding from HLB Co., Ltd. and other investor.
18/10/20
CI
Mediforum Pharmaceutical Incorporation announced that it has received KRW 48.632978215 billion in funding from EBEST Investment & Securities Co., Ltd., Medi Forum Co.,Ltd., HLB Co., Ltd.
09/09/20
CI
Mediforum Pharmaceutical Incorporation announced that it expects to receive KRW 20 billion in funding from HLB Co., Ltd. and other investor
30/08/20
CI
Mediforum Pharmaceutical Incorporation announced that it expects to receive KRW 20 billion in funding from Ibest Investment Company Ltd., Hanyang Securities Co. Ltd., Investment Arm, EBEST Investment & Securities Co., Ltd.
26/04/20
CI
Mediforum Will Collaborate with Supertrans in the Manufacturing and Commercialization of Supertrans' Products in Asia, Including South Korea, China, and Japan
07/04/20
CI
SuperTrans Medical announced that it expects to receive $2 million in funding from Mediforum Pharmaceutical Incorporation
06/04/20
CI
Mediforum Pharmaceutical Incorporation announced that it expects to receive KRW 9.90000095 billion in funding
23/02/20
CI
Mediforum Co.,Ltd. acquired 13.9% stake in C-TRI Co., Ltd. from DAE HWA Pharmaceutical Co., Ltd. and Wanjoo Kim for KRW 20.2 billion.
04/12/19
CI
Mediforum Pharmaceutical Incorporation announced that it expects to receive KRW 48.632978215 billion in funding from EBEST Investment & Securities Co., Ltd., Medi Forum Co.,Ltd., HLB Co., Ltd.
15/10/19
CI
DelSiTech Ltd and C-Tri Co. Ltd Sign Collaboration Agreement to Develop Innovative Drug Delivery Technology Product for Oncology
18/12/17
CI
C-TRI Co., Ltd. announced that it has received KRW 15 billion in funding from Kiwoom Securities Co., Ltd., Investment Arm, Synergy Partners Co., Ltd., Timefolio Co.,Ltd., Lime Asset Management Co., Ltd., ANDA Asset Management Co., Ltd.
27/07/16
CI
C-TRI Co., Ltd. announced that it expects to receive KRW 15 billion in funding from Kiwoom Securities Co., Ltd., Investment Arm, Synergy Partners Co., Ltd., Timefolio Co.,Ltd., Lime Asset Management Co., Ltd., ANDA Asset Management Co., Ltd.
26/07/16
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
HLB Pharmaceutical Co Ltd, formerly Mediforum Pharmaceutical Inc, is a Korea-based company mainly engaged in the manufacture and distribution of pharmaceutical products. The Company mainly manufactures and sells pharmaceutical products including cimetidine tablets, rozatin tablets, rabeprazole tablets, rozatinplus tablets, mosapia tablets and other ethical the counter (ETC) drugs; gynobetadine vaginal suppositories, and other over the counter (OTC) drugs; aceclofenac tablets, revotec tablets and other commissioned ETC drugs; L-carnitine tablets, elcatan tablets, hepatine liquids and other commissioned OTC drugs.
More about the company
1st Jan change
Capi.
+49.24% 196M +37.69% 727B -7.91% 354B +15.64% 328B -0.45% 277B +13.47% 243B +7.35% 205B -6.42% 203B +3.79% 164B -2.07% 164B
Other Pharmaceuticals
+951% of historical
More than 20 years
Our Experts
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
HLB PHARMACEUTICAL CO., LTD. 
